Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Abstract Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy ( n = 30) and in combination with atezolizumab ( n = 183) in pretreated patients with advanced solid tumors. The primary objective was safety and tolerability; exploratory objectives included evaluation of pharmacokinetics,…

• MG
  Massachusetts General Hospital
• YU
  Yale University
• GS
  Gilead Sciences
• MS
  Memorial Sloan-Kettering Cancer Center
• UO
  University of Washington
• UO
  University of Oklahoma
• DK
  Deutsches Krebsforschungszentrum
• QM
  Queen Mary University of London
• UH
  University Hospital Southampton NHS Foundation Trust
• YC
  Yale Cancer Center
• CM
  Cedars-Sinai Medical Center
• S
  Seagen
• UO
  University of Southampton
• UZ
  Universitair Ziekenhuis Gent
• JG
  Johannes Gutenberg-Universität Mainz
• UG
  Universiteit Gent
• UD
  Universidad de Navarra
• AS
  Akademiska Sjukhuset
• UU
  Uppsala Universitet
• CD
  Centro de Investigación Biomédica en Red de Cáncer
• G
  Genentech
• WC
  Weill Cornell Medical College
• UO
  University of Oklahoma Health Sciences Center
• UO
  University of California, San Francisco
• CC
  Cancer Center, University of Colorado
• UD
  Universitätsmedizin der Johannes Gutenberg-Universität Mainz
• HD
  Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco